A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Pegfilgrastim (Primary) ; Plinabulin (Primary)
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms PROTECTIVE-2
- Sponsors BeyondSpring Pharmaceuticals
- 13 Sep 2022 Results by obtaining data from PROTECTIVE-1 and PROTECTIVE-2, evaluating plins protective effects on granulocyte-monocyte progenitor , presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented in a BeyondSpring Pharmaceuticals media release.
- 13 Sep 2022 According to BeyondSpring Pharmaceuticals media release, data from this study were presented at the ESMO Congress 2022.